Please assess the completion status of the following clinical trial:

Trial Title: Effects of Anti-Glaucoma Medications on the Ocular Surface

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be 18 years of age and may be of any race and either gender;~* Subjects must not have ever used topical prostaglandin anti-glaucomatous therapy;~  * Subject has not used anti-glaucomatous treatment in the past 30 days and has not been using prescribed anti-glaucomatous medication for more than 6 months.~ * Subject is using other topical anti-glaucomatous topical treatment and wants to switch to a prostaglandin (must have undergone 30 day washout period)~* The IRB Approved informed consent and the privacy document must be read, signed, and dated by the subject or legally authorized representative before enrollment. Additionally, the informed consent document must be signed and dated by the individual consenting the subject, as well as signed and dated by a witness, if applicable;~* Subjects must be generally healthy and have normal ocular health; and~* Subjects must be willing to follow the study procedures and visit schedule.~Exclusion Criteria:~* Subjects must not have known sensitivities to any ingredient in any of the test articles~* Subjects must not have any systemic or ocular disease or disorder (exc refractive error), complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study:~  * No prior (within 30 days of enrollment) or current ocular infections (bacterial, viral or fungal), active ocular inflammation (i.e., follicular conjunctivitis, allergic conjunctivitis, iritis), glaucoma, or preauricular lymphadenopathy.~ * No clinically significant lash or lid abnormality (e.g., trichiasis, entropion or ectropion).~ * No uncontrolled systemic disease or debilitating disease (e.g. cardiovascular disease, hypertension, diabetes, or cystic fibrosis.).~ * No prior (within 7 days of enrollment) or current, unstable active illness (e.g., upper respiratory infection).~* Pregnant woman~* Subjects must not have history of ocular surgery/trauma within the last 6 months~* Subjects must not have used any topical ocular or systemic antibiotics within 30 days of enrollment continuing throughout the study~* Subjects must not have used any topical ocular or systemic corticosteroids within 30 days of enrollment continuing throughout the study~* Subjects must not have used immunomodulator medications within 30 days of enrollment continuing throughout the study~* Subjects must not have a immune cell density of \>60/fame present at their baseline confocal scan~* Subjects must not have participated in any other ophthalmic drug or device clinical trial within 30 days of enrollment.~* Inability to cooperate with the confocal exam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Latanoprost (Xalatan) (Type: ACTIVE_COMPARATOR): 7 Patients were randomized to receive BAK-containing Xalatan for treatment of their glaucoma.
- Travoprost (Travatan Z) (Type: ACTIVE_COMPARATOR): 7 Patients were randomized to receive BAK-free Travatan Z for treatment of their glaucoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).